MENLO PARK, Calif.
July 3, 2013
/PRNewswire/ -- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced the presentations of the latest data on its Eeva™ Test at the 29
annual meeting of the European Society of Human Reproduction and Embryology (ESHRE). The meeting will be held
July 7 through 10
These presentations follow the recent announcement about the births of the world's first two babies conceived using the Eeva Test at the Hewitt Fertility Centre,
and the Glasgow Centre for Reproductive Medicine (GCRM),
"The Eeva Test has been developed to give IVF clinicians valuable and objective information about the embryo, and provide insight into its growth potential,"
, president and CEO of Auxogyn, said. "Auxogyn is committed to advancing reproductive medicine to help address the growing number of patients suffering from infertility today and to supporting the efforts of IVF clinicians to increase a couple's chance of conceiving a child."
Notable data from Auxogyn at ESHRE 2013 include:
- Embryos with good morphology but abnormal cell divisions have significantly lower implantation potential – Monday, July 8, 11:45-12:15 BST
- A prospective, multicenter cohort study of the Eeva Test among 160 women undergoing fresh IVF treatment
- Abnormal syngamy phenotypes observed with time-lapse imaging may allow early identification of embryos with lower development potential – Wednesday, July 10, 10:30-10:45 BST
- A retrospective cohort study of syngamy (the breakdown of the pronuclei when the two sets of chromosomes unite) using image data from the Eeva Test collected from 70 patients
- Dynamic assessment of early embryo fragmentation by time-lapse analysis may improve cell cycle timing-based embryo selection – Poster P-186 – Monday-Wednesday, July 8-10, 08:30-17:00 BST
- A retrospective analysis of 850 embryos from 95 patients whose embryos were imaged using the Eeva Test
Full session details and data presentation listings for the 2013 meeting can be found on the ESHRE website at
Auxogyn is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into clinical tools. The Company's flagship product, the Eeva™ Test, delivers consistent, objective information regarding embryo viability that IVF clinicians and patients can use to make important treatment decisions. Auxogyn is privately held and funded by Kleiner Perkins Caufield & Byers, Merck Serono Ventures, SR One and TPG Biotech. For more information visit
and follow us on Twitter @Auxogyn.
About the Early Embryo Viability Assessment (Eeva™) Test
The Eeva Test provides IVF clinicians with predictive information about the embryo's development potential to help improve embryo selection. Eeva proprietary software automatically analyzes embryo development against scientifically and clinically validated cell-division parameters conceived by researchers at Stanford University in the US. With results from the Eeva Test, IVF teams now have predictive and objective information to combine morphological assessment to help improve the embryo selection decision. The Eeva Test was validated in a prospective, multi-centre, 54-patient clinical trial with 758 embryos. Embryologists using Eeva Test were significantly able to improve their ability to identify non-viable embryos relative to traditional methods alone. Additionally, the Eeva Test was able to increase the consistency of embryo assessment across embryologists. Results of this study were presented in July 2012 at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting and published by Conaghan et al in Fertility and Sterility, May 2013.
The Eeva Test is CE Marked and available for use in the EU and is pending FDA clearance in the United States. For a full list of clinics in the EU offering the Eeva Test please visit
or follow us on Twitter @EevaIVF.
SOURCE Auxogyn, Inc.